Zentalis Pharmaceuticals

Small Molecules

Also 5 additional trials Clin1/Clin2 multiple cancers; ZN-c5 Clin2 (development to be discontinued after trial) breast cancer (partner Zentera); Zn-d5 (partner: Zentera) Clin1 AL amyloidosis, Clin1 AML, NHL, combo Clin0 AML; Zn-e4 (partner: SciClone Pharmaceuticals) Clin1 (development to be discontinued after trial) NSCLC; undisclosed Clin0 multiple cancers

Zentalis Pharmaceuticals is developing small molecule therapeutics targeting fundamental biological pathways of cancers. The company's unique science is based on its proprietary Integrated Discovery Engine (IDE), which combines expertise in medicinal chemistry, computational biology, and translational oncology to identify and develop novel drug candidates. Zentalis' IDE has the potential to accelerate the drug discovery process and identify more effective and less toxic drug candidates than traditional approaches. The company's lead product candidate, azenosertib, is a Wee1 inhibitor that is currently in Phase 3 clinical trials for the treatment of ovarian cancer.